Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-10-31Clinical Trial Update: AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment [NA]
A completed clinical trial evaluating the LEAP AI-assisted evaluation platform versus clinician-only assessment in acute promyelocytic leuke…
-
CLINICAL_TRIALS research · 2025-10-31Clinical Trial Update: A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) [Phase 2]
Phase 2 study update for participants who previously took ASTX727 (oral decitabine/cedazuridine) that is currently enrolling by invitation.
-
CLINICAL_TRIALS research · 2025-10-31Clinical Trial Update: Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome [Phase 2]
A Phase 2 trial evaluating ruxolitinib with tacrolimus and methotrexate to prevent graft-versus-host disease in pediatric and young adult pa…
-
CLINICAL_TRIALS research · 2025-10-31Clinical Trial Update: Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]
Phase 1 clinical trial update for NMS-03597812 in adults with relapsed/refractory acute myeloid leukemia; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning before allogeneic donor stem cell transplantation in patients with high-risk hematol…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-30Clinical Trial Update: Two Step Haplo With Radiation Conditioning [Phase 2]
Phase 2 clinical trial update describing two-step haploidentical transplantation with radiation conditioning for hematologic diseases, curre…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant [Phase 2]
This clinical trial update reports that the Phase 2 study of MT-401 in patients with acute myeloid leukemia following stem cell transplantat…
-
CLINICAL_TRIALS trial_result · 2025-10-28Clinical Trial Update: Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia [Phase 1]
A Phase 1 study evaluating a combination of Gemtuzumab ozogamicin and Midostaurin with standard cytarabine and daunorubicin in newly diagnos…
-
CLINICAL_TRIALS trial_result · 2025-10-28Clinical Trial Update: Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance [Phase 2]
This Phase 2 trial update describes a precision genomic strategy to assess mutation clearance in acute myeloid leukemia. The study is curren…
-
CLINICAL_TRIALS research · 2025-10-27Clinical Trial Update: UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia [Phase 2]
Phase 2 clinical trial update for UM171 expanding cord blood in patients with high-risk acute leukemia or myelodysplastic syndromes. The stu…
-
CLINICAL_TRIALS trial_result · 2025-10-27Clinical Trial Update: Resiliency in Older Adults Undergoing Bone Marrow Transplant
A completed clinical trial update from Johns Hopkins on resiliency in older adults undergoing bone marrow transplant for hematologic cancers…
-
CLINICAL_TRIALS trial_result · 2025-10-22Clinical Trial Update: CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating a CD8-depleted, non-engrafting, HLA-mismatched unrelated donor infusion in patients with myelodysplastic…
-
CLINICAL_TRIALS trial_result · 2025-10-22Clinical Trial Update: Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML [Phase 1]
Phase 1 clinical trial update evaluating eganelisib as a monotherapy and in combination with cytarabine in relapsed/refractory acute myeloid…
-
CLINICAL_TRIALS research · 2025-10-21Clinical Trial Update: Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
This Phase 1 clinical trial evaluates the combination of nintedanib and azacitidine in adults with HOX gene overexpression acute myeloid leu…
-
CLINICAL_TRIALS research · 2025-10-21Clinical Trial Update: Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 1]
This entry reports a Phase 1 trial of Tomivosertib in relapsed or refractory acute myeloid leukemia, sponsored by Northwestern University; t…
-
CLINICAL_TRIALS trial_result · 2025-10-21Clinical Trial Update: Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) [Phase 1]
Phase 1 clinical trial evaluating the administration of donor-derived multi TAA-specific T cells (ADSPAM) for acute myeloid leukemia or myel…
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia [Phase 1, Phase 2]
Phase 1/2 study evaluating uproleselan with cladribine and low-dose cytarabine in patients with treated secondary acute myeloid leukemia; re…
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia [Phase 1]
Phase 1 trial update for entrectinib in combination with ASTX727 in relapsed/refractory TP53-mutated acute myeloid leukemia; the study is cu…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: IS-free Treg HaploHCT [Phase 1]
A Phase 1 clinical trial at Dana-Farber Cancer Institute evaluating an IS-free regulatory T cell haploidentical hematopoietic cell transplan…
-
CLINICAL_TRIALS trial_result · 2025-10-16Clinical Trial Update: Epigenetic Reprogramming in Relapse/Refractory AML [Phase 1]
Phase 1 clinical trial update reports results of an epigenetic reprogramming therapy for relapse/refractory acute myeloid leukemia, with res…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors [Phase 1]
Phase 1 pediatric trial evaluating alpha/beta CD19+ depleted haploidentical transplantation in combination with Zoledronic acid (Zometa) for…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS [NA]
Clinical trial investigating whole genome sequencing (ChromoSeq) as an adjunct to conventional genomic profiling in acute myeloid leukemia a…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome [Phase 1, Phase 2]
This trial evaluates a targeted radiopharmaceutical (211At-BC8-B10) followed by an allogeneic donor stem cell transplant for relapsed or ref…
-
CLINICAL_TRIALS research · 2025-10-15Clinical Trial Update: Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating naive T cell depletion to prevent chronic graft-versus-host disease in children and young adults receiving…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: CD123 Redirected T Cells for AML in Pediatric Subjects [Phase 1]
Phase 1 trial of CD123-targeted T cells for acute myeloid leukemia in pediatric patients and those with relapse or refractory disease has be…